This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neyts, J.
Right arrow Articles by De Clercq, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neyts, J.
Right arrow Articles by De Clercq, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2001, p. 84-87, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.84-87.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Efficacy of 2-Amino-7-(1,3-Dihydroxy-2-Propoxymethyl)Purine for Treatment of Vaccinia Virus (Orthopoxvirus) Infections in Mice

Johan Neyts* and Erik De Clercq

Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium

Received 15 June 2000/Returned for modification 19 September 2000/Accepted 10 October 2000

We have previously shown that the N-7 substituted acyclic nucleoside analog 2-amino-7-[1,3-dihydroxy-2-propoxy)methyl]purine (compound S2242) is, both in vitro and in animal models, a potent inhibitor of the replication of several herpesviruses (Neyts et al., Antimicrob. Agents Chemother. 39:56-60, 1995). Here we report on the potent and selective antiviral activity of S2242 against vaccinia virus (VV), an orthopoxvirus. The 50% effective concentrations for inhibition of VV-induced cytopathic effect and viral DNA synthesis in cell culture were 2.4 and 0.2 µg/ml, respectively. We next studied the efficacy of S2242 in VV-infected mice. Immunocompetent NMRI mice that had been inoculated intravenously with VV developed tail lesions. Mice that had been treated for 5 consecutive days via the subcutaneous (s.c.) route with 100 mg of the diacetate ester prodrug of S2242 (compound H961) per kg of body weight did not develop any lesions and demonstrated no adverse effects. Severe combined immunodeficient (SCID) mice that had been inoculated intraperitoneally with VV became sick and died within 1 month after infection. Following treatment with H961 at 100 mg/kg for 10 consecutive days (either via oral gavage or s.c. injection) VV-inoculated SCID mice were completely protected, for at least 3 months, against virus-induced morbidity and mortality. At that time, no virus could be recovered from the organs of these mice (as assessed by titration for infectious virus, a DNA hybridization assay, and a PCR for VV-specific sequences). Compound S2242 and its oral prodrug H961 could be useful in treatment of orthopoxvirus infections.

* Corresponding author. Mailing address: Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Phone: 32 16 337341. Fax: 32 16 337340. E-mail: Johan.Neyts{at}rega.kuleuven.ac.be.

Antimicrobial Agents and Chemotherapy, January 2001, p. 84-87, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.84-87.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Kornbluth, R. S., Smee, D. F., Sidwell, R. W., Snarsky, V., Evans, D. H., Hostetler, K. Y. (2006). Mutations in the E9L Polymerase Gene of Cidofovir-Resistant Vaccinia Virus Strain WR Are Associated with the Drug Resistance Phenotype. Antimicrob. Agents Chemother. 50: 4038-4043 [Abstract] [Full Text]  
  • Shearer, J. D., Siemann, L., Gerkovich, M., House, R. V. (2005). Biological Activity of an Intravenous Preparation of Human Vaccinia Immune Globulin in Mouse Models of Vaccinia Virus Infection. Antimicrob. Agents Chemother. 49: 2634-2641 [Abstract] [Full Text]  
  • Naesens, L., Lenaerts, L., Andrei, G., Snoeck, R., Van Beers, D., Holy, A., Balzarini, J., De Clercq, E. (2005). Antiadenovirus Activities of Several Classes of Nucleoside and Nucleotide Analogues. Antimicrob. Agents Chemother. 49: 1010-1016 [Abstract] [Full Text]  
  • Neyts, J., Leyssen, P., Verbeken, E., De Clercq, E. (2004). Efficacy of Cidofovir in a Murine Model of Disseminated Progressive Vaccinia. Antimicrob. Agents Chemother. 48: 2267-2273 [Abstract] [Full Text]  
  • Quenelle, D. C., Collins, D. J., Kern, E. R. (2003). Efficacy of Multiple- or Single-Dose Cidofovir against Vaccinia and Cowpox Virus Infections in Mice. Antimicrob. Agents Chemother. 47: 3275-3280 [Abstract] [Full Text]  
  • Neyts, J., Verbeken, E., De Clercq, E. (2002). Effect of 5-Iodo-2'-Deoxyuridine on Vaccinia Virus (Orthopoxvirus) Infections in Mice. Antimicrob. Agents Chemother. 46: 2842-2847 [Abstract] [Full Text]  
  • Kern, E. R., Hartline, C., Harden, E., Keith, K., Rodriguez, N., Beadle, J. R., Hostetler, K. Y. (2002). Enhanced Inhibition of Orthopoxvirus Replication In Vitro by Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir. Antimicrob. Agents Chemother. 46: 991-995 [Abstract] [Full Text]  
  • De Clercq, E. (2001). Vaccinia Virus Inhibitors as a Paradigm for the Chemotherapy of Poxvirus Infections. Clin. Microbiol. Rev. 14: 382-397 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»